Truqap Offers New Hope for HR+/HER2- Breast Cancer Treatment in Korea
Truqap (capivasertib), the first AKT inhibitor, is now available in Korea for HR+/HER2- locally advanced or metastatic breast cancer patients with PIK3CA, AKT1, and PTEN mutations.